- AbbVie Inc (NYSE:ABBV) and Immunome Inc (NASDAQ:IMNM) announced a worldwide collaboration and option agreement to discover up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome’s Discovery Engine.
- Immunome will receive an upfront payment of $30 million. It will be eligible to receive additional platform access payments in the aggregate amount of up to $70 million based on AbbVie’s election for Immunome to continue research using its Discovery Engine.
- Related: Immunome’s COVID-19 Cocktail Retains Neutralizing Activity Against Omicron Subvariants.
- Immunome is also eligible to receive development and first commercial sale milestones of up to $120 million per target with respect to certain products derived from target-antibody pairs that AbbVie elects to purchase, with potential for further sales-based milestones as well as tiered royalties on global sales.
- Price Action: IMNM shares are up 5.52% at $4.97 on the last check Friday.
Inventiva Announces That Its Partner Sino Biopharm Received IND Approval From The NMPA To Initiate Clinical Trial With Lanifibranor In China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd., a Sino Biopharm's subsidiary, receives IND approval from the NMPA to initiate the clinical development in mainland China of lanifibranor in NASH
Sino Biopharm will
